Comparative Pharmacology
Head-to-head clinical analysis: ADLYXIN versus TANZEUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLYXIN versus TANZEUM.
ADLYXIN vs TANZEUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
Subcutaneous injection: 300 mg every 4 weeks. Administer as 3 consecutive injections of 100 mg each in the same body region (abdomen, thigh, or upper arm).
None Documented
None Documented
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
Terminal elimination half-life approximately 5 days (range 4-6 days), supporting weekly subcutaneous dosing
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Renal (79% as unchanged drug), biliary/fecal (minor, ~1%)
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist